Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 6/20 | 0.48 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262647 | 0.85 | SCD (0.48) | SCDSCD5FFAR1FFAR4LMNA | |
| SCHEMBL3102844 | 0.81 | SCD (0.69) | SCDSCD5FFAR1FFAR4LMNA | |
| SCHEMBL3323016 | 0.78 | SCD (0.43) | SCDSCD5FFAR1FFAR4GRM2 | |
| SCHEMBL3323942 | 0.76 | SCD (0.54) | SCDSCD5FFAR1FFAR4LMNA | |
| SCHEMBL3232055 | 0.74 | SCD (0.47) | SCDSCD5GRM2LMNAPOLB | |
| SCHEMBL3325378 | 0.74 | SCD (0.51) | SCDSCD5LMNAPOLBKDM4E | |
| SCHEMBL3235762 | 0.71 | SCD (0.55) | SCDSCD5FFAR1FFAR4PKM | |
| SCHEMBL3100399 | 0.71 | FFAR1 (0.48) | SCDSCD5FFAR1FFAR4LMNA | |
| SCHEMBL3324510 | 0.69 | SCD (0.42) | SCDSCD5FFAR1FFAR4GRM2 | |
| SCHEMBL3236099 | 0.68 | FFAR1 (0.51) | SCDSCD5FFAR1FFAR4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120784-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
| EP-2148878-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2010-02-03 | — | — | EP | disclosed |
| WO-2008128335-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120784-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, ACSL6 | SCD 1/4885SCD5 2/4885FFAR1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.